Corvus Pharmaceuticals appoints Andrew C. Chan to board; Scott Morrison resigns

Corvus Pharmaceuticals, Inc.

Andrew C. Chan appointed as Class II director, effective April 23, 2026, term through 2027 annual meeting.
Chan receives $35,000 annual retainer, $4,000 Nominating Committee fee, and initial option for 30,000 shares.
Scott Morrison resigned from board effective April 23, 2026 after over a decade of service.
Chan also appointed to the Nominating Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.